Literature DB >> 35510137

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Simone de Campos Vieira Abib1, Chan Hon Chui2, Sharon Cox3, Abdelhafeez H Abdelhafeez4, Israel Fernandez-Pineda5, Ahmed Elgendy6, Jonathan Karpelowsky7, Pablo Lobos8, Marc Wijnen9, Jörg Fuchs10, Andrea Hayes11, Justin T Gerstle12.   

Abstract

Most children with tumors will require one or more surgical interventions as part of the care and treatment, including making a diagnosis, obtaining adequate venous access, performing a surgical resection for solid tumors (with staging and reconstruction), performing procedures for cancer prevention and its late effects, and managing complications of treatment; all with the goal of improving survival and quality of life. It is important for surgeons to adhere to sound pediatric surgical oncology principles, as they are closely associated with improved local control and survival. Unfortunately, there is a significant disparity in survival rates in low and middle income countries, when compared to those from high income countries. The International Society of Paediatric Surgical Oncology (IPSO) is the leading organization that deals with pediatric surgical oncology worldwide. This organization allows experts in the field from around the globe to gather and address the surgical needs of children with cancer. IPSO has been invited to contribute surgical guidance as part of the World Health Organization Initiative for Childhood Cancer. One of our goals is to provide surgical guidance for different scenarios, including those experienced in High- (HICs) and Low- and Middle-Income Countries (LMICs). With this in mind, the following guidelines have been developed by authors from both HICs and LMICs. These have been further validated by experts with the aim of providing evidence-based information for surgeons who care for children with cancer. We hope that this initiative will benefit children worldwide in the best way possible. Simone Abib, IPSO President Justin T Gerstle, IPSO Education Committee Chair Chan Hon Chui, IPSO Secretary. © the authors; licensee ecancermedicalscience.

Entities:  

Keywords:  children; paediatric cancer; paediatric oncology surgery; surgery

Year:  2022        PMID: 35510137      PMCID: PMC9023308          DOI: 10.3332/ecancer.2022.1356

Source DB:  PubMed          Journal:  Ecancermedicalscience        ISSN: 1754-6605


  1025 in total

Review 1.  Testicular choriocarcinoma: a rare variant that requires a unique treatment approach.

Authors:  Matthew James Reilley; Lance C Pagliaro
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

2.  Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.

Authors:  Dimitrios Nasioudis; Michail Alevizakos; Kevin Holcomb; Steven S Witkin
Journal:  Maturitas       Date:  2016-11-15       Impact factor: 4.342

3.  Pediatric pancreatic tumors: the orphan looking for a home.

Authors:  Bernadette Brennan
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

4.  Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991.

Authors:  R B Raney; L Asmar; W A Newton; C Bagwell; J C Breneman; W Crist; E A Gehan; B Webber; M Wharam; E S Wiener; J R Anderson; H M Maurer
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Primary lung tumors in children and adolescents: a 90-year experience.

Authors:  David C Yu; Matthew J Grabowski; Harry P Kozakewich; Antonio R Perez-Atayde; Stephan D Voss; Robert C Shamberger; Christopher B Weldon
Journal:  J Pediatr Surg       Date:  2010-06       Impact factor: 2.545

6.  Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.

Authors:  Alberto S Pappo; Meenakshi Devidas; Jessee Jenkins; Bhaskar Rao; Robert Marcus; Patrick Thomas; Mark Gebhardt; Charles Pratt; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

7.  Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study.

Authors:  J Godzinski; F Flamant; A Rey; M T Praquin; H Martelli
Journal:  Med Pediatr Oncol       Date:  1994

8.  PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Authors:  Agnès Chompret; Caroline Kannengiesser; Michel Barrois; Philippe Terrier; Philippe Dahan; Thomas Tursz; Gilbert M Lenoir; Brigitte Bressac-De Paillerets
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

9.  Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group.

Authors:  P Czauderna; G Mackinlay; G Perilongo; J Brown; E Shafford; D Aronson; J Pritchard; P Chapchap; J Keeling; J Plaschkes; J B Otte
Journal:  J Clin Oncol       Date:  2002-06-15       Impact factor: 44.544

Review 10.  Fluorescence-Guided Surgery for Hepatoblastoma with Indocyanine Green.

Authors:  Yohei Yamada; Michinobu Ohno; Akihiro Fujino; Yutaka Kanamori; Rie Irie; Takako Yoshioka; Osamu Miyazaki; Hajime Uchida; Akinari Fukuda; Seisuke Sakamoto; Mureo Kasahara; Kimikazu Matsumoto; Yasushi Fuchimoto; Ken Hoshino; Tatsuo Kuroda; Tomoro Hishiki
Journal:  Cancers (Basel)       Date:  2019-08-20       Impact factor: 6.639

View more
  2 in total

1.  Conference report on the 14th International Society of Paediatric Oncology African Continental Meeting, 16-18 March 2022, Kampala, Uganda.

Authors:  Jaques van Heerden; Lisa Christine Irumba; Karim Assani; Julia Downing; Alan Davidson; Laila Hessissen; Judy Schoeman; Trijn Israels; Sharon Cox; Hafeez Abdelhafeez; Shauna Odongo Arao; Jeannette Parkes; Joyce Balagadde-Kambugu; Jennifer Geel
Journal:  Ecancermedicalscience       Date:  2022-07-07

Review 2.  Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.

Authors:  Sara R Martins-Neves; Gabriela Sampaio-Ribeiro; Célia M F Gomes
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.